| __timestamp | CRISPR Therapeutics AG | Dyne Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 1145000000 |
| Thursday, January 1, 2015 | 12573000 | 2028000000 |
| Friday, January 1, 2016 | 42238000 | 2281000000 |
| Sunday, January 1, 2017 | 69800000 | 2932000000 |
| Monday, January 1, 2018 | 113773000 | 24000 |
| Tuesday, January 1, 2019 | 179362000 | 271000 |
| Wednesday, January 1, 2020 | 269407000 | 700000 |
| Friday, January 1, 2021 | 17953000 | 1088000 |
| Saturday, January 1, 2022 | 110250000 | 3345000 |
| Sunday, January 1, 2023 | 130250000 | 2461000 |
| Monday, January 1, 2024 | -2314000 |
Unleashing insights
In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis compares the cost of revenue for CRISPR Therapeutics AG and Dyne Therapeutics, Inc. over the past decade. CRISPR Therapeutics, a pioneer in gene-editing technology, has seen its cost of revenue grow steadily, peaking in 2020 with a 1,680% increase from 2014. Meanwhile, Dyne Therapeutics, focusing on muscle diseases, experienced a dramatic fluctuation, with a notable spike in 2017, followed by a significant drop in subsequent years.
From 2014 to 2023, CRISPR Therapeutics maintained a consistent upward trend, reflecting its expanding operations and market reach. In contrast, Dyne Therapeutics' cost of revenue was more volatile, highlighting the challenges and unpredictability in the biotech sector. This comparison underscores the diverse financial landscapes within the industry, offering valuable insights for strategic decision-making.
Eli Lilly and Company vs Dyne Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Pfizer Inc. vs CRISPR Therapeutics AG
Comparing Cost of Revenue Efficiency: Bristol-Myers Squibb Company vs Dyne Therapeutics, Inc.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and CRISPR Therapeutics AG's Expenses
Cost of Revenue: Key Insights for Biogen Inc. and Dyne Therapeutics, Inc.
Cost of Revenue Comparison: Grifols, S.A. vs CRISPR Therapeutics AG
Comparing Cost of Revenue Efficiency: CRISPR Therapeutics AG vs Ligand Pharmaceuticals Incorporated
CRISPR Therapeutics AG vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: CRISPR Therapeutics AG vs Wave Life Sciences Ltd.
Cost Insights: Breaking Down CRISPR Therapeutics AG and Viridian Therapeutics, Inc.'s Expenses
Cost of Revenue Comparison: ACADIA Pharmaceuticals Inc. vs Dyne Therapeutics, Inc.
Cost of Revenue Comparison: Bausch Health Companies Inc. vs Dyne Therapeutics, Inc.